99PD - High proportion of complete radiologic and metabolic response and prolonged progression-free survival after intercalated chemotherapy and erlotinib...

Date 28 March 2014
Event ELCC 2014
Session Poster Discussion 2
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Matjaz Zwitter
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors M. Zwitter, V. Kovac
  • Department Of Radiotherapy, Institute of Oncology, 1000 - Ljubljana/SI


NSCLC with activating EGFR mutations is a tumor sensitive to both tyrosine kinase inhibitors (TKIs) and to cytotoxic drugs. To avoid their mutual antagonistic effect and still derive benefit from the combination, pharmaco-dynamic separation of the two classes of drugs has been proposed. Here we present experience from a Phase 2 trial on patients with advanced NSCLC without prior systemic treatment and with confirmed activating EGFR mutations.